Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $7.00.

ESPR has been the subject of several other reports. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.87 on Tuesday. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The firm has a market cap of $368.46 million, a P/E ratio of -2.92 and a beta of 1.01. The stock’s 50-day moving average is $2.24 and its 200-day moving average is $2.12.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Traphagen Investment Advisors LLC acquired a new position in shares of Esperion Therapeutics in the third quarter valued at approximately $27,000. Cibc World Markets Corp bought a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $39,000. Versor Investments LP acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $44,000. SJS Investment Consulting Inc. bought a new position in Esperion Therapeutics in the fourth quarter valued at about $55,000. Finally, Boomfish Wealth Group LLC grew its stake in shares of Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares during the last quarter. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.